- Third approved indication for SKYRIZI (risankizumab-rzaa) is supported by safety and efficacy data from two induction and one maintenance clinical trials evaluating SKYRIZI in moderately to severely ...
NORTH CHICAGO, Ill., June 18, 2024 /PRNewswire/ — AbbVie (NYSE: ABBV) today announced the U.S. Food and Drug Administration (FDA) has approved SKYRIZI ® (risankizumab-rzaa) for adults with moderately ...
NORTH CHICAGO, Ill., June 15, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive top-line results from COMMAND, its Phase 3 maintenance study, showing risankizumab (SKYRIZI ®, 180 mg or ...
NORTH CHICAGO, Ill., April 7, 2021 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced that it has submitted applications seeking approval for SKYRIZI® (risankizumab-rzaa, 150 mg) to the U.S. Food and ...
Crohn’s disease can be treated with medications that control inflammation and reduce the frequency of flareups for the intestinal disorder. These treatments include biologic drugs that target certain ...
AbbVie already has high hopes for newly approved immunology drug Skyrizi as its old megablockbuster Humira starts to fall. Now, it has rolled out results to back longer-term use of the new IL-23 ...
Skyrizi (risankizumab-rzaa) is a biologic medication doctors prescribe to treat certain autoimmune and inflammatory conditions. Like any medication, it can cause side effects. But is one of Skyrizi’s ...
Submissions are supported by two Phase 3 clinical trials demonstrating risankizumab achieved the primary endpoint of clinical remission (per Adapted Mayo Score) and key secondary endpoints as an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback